HEALTH

Single application earwax removal solution launched through Amazon

BY Michael Johnsen

FORT WORTH, Texas — Eosera on Tuesday launched their earwax dissolving product, Earwax MD, through Amazon Exclusives. The product comes in two sizes, a kit that includes a 15mL bottle and rinsing bulb, and a single 15mL bottle only.

"When I met with Amazon, we decided it would be wonderful to launch with them because they reach all consumers," stated Elyse Dickerson, CEO Eosera. "Our earwax solution will help people worldwide and Amazon is the first step. By bringing this novel innovation to market, our goal is to improve the lives of both doctors and patients by saving people time and money."

The product was first introduced to hearing aid centers and audiologists in April.

According to Eosera, Earwax MD is the healthcare industry's first earwax impaction solution to safely and effectively dissolve wax blockage in a single application. "Instead of having to dig out earwax, audiologists and hearing aid centers can now fit patients for hearing aids in one visit," she said.

 

keyboard_arrow_downCOMMENTS

Leave a Reply

No comments found

TRENDING STORIES

Polls

Which area of the industry do you think Amazon's entry would shake up the most?
HEALTH

New clinical data supports efficacy of OTC PE treatment PreBoost

BY Michael Johnsen

MIAMI — Veru Healthcare on Saturday announced positive results from a Phase 4 clinical study of its proprietary product PreBoost (topical 4% benzocaine wipes) for the management of premature ejaculation. Data showed that PreBoost wipes statistically and significantly improved both objective and subjective symptoms of PE when compared to placebo wipes.

Results were selected for inclusion in the American Urological Association’s Annual Meeting Press Conference, held Saturday morning in Boston. The data will also be shared during a podium presentation on May 16, Veru Healthcare noted.

“Premature ejaculation or PE is the most common sexual dysfunction, affecting one in four men, yet we have limited options that really help men manage it,” stated study investigator and presenter Ridwan Shabsigh, chairman surgery, SBH Health System and professor clinical urology at Weill-Cornell Medical School. “These data represent the first ever placebo-controlled clinical study of medicines available in this class of products.”

After treatment with PreBoost, 82% of men were no longer considered to have PE while being treated and reported a statistically significant better sense of control, confidence, satisfaction, pleasure, increased length of intercourse and reduced frustration. Treatment was well tolerated and no transference of product was reported.

“We’re excited about these clinical data and what our product can do for men who have really had no options and desire a simple solution to PE,” commented Mitchell Steiner, president and CEO Veru Healthcare. “These Phase 4 data represent the first clinical study ever to show clinical data of an OTC product for the management of premature ejaculation.”
 

keyboard_arrow_downCOMMENTS

Leave a Reply

m.leo says:
May-19-2017 04:00 am

This is really misleading, there has been a superior product on the market for 5 years. Promescent has a eutectic formula that leaves the man with more sensitivity while not transferring to the female partner. This supposed study has only 26 participants is not IRB certified and not statistically significant. Promescent is already well established and respected in the urological community and is also OTC. 

TRENDING STORIES

Polls

Which area of the industry do you think Amazon's entry would shake up the most?
HEALTH

Hi-Tech Pharmaceuticals targets cholesterol-lowering supplements through new JV

BY Michael Johnsen

NORCROSS, Ga. — Hi-Tech Pharmaceuticals  on Thursday created a joint venture with Chinese conglomerate Shanghai Yongyi Biotechnology to be called Yongyi Hi-Tech Nutraceuticals. The company's mission will be to develop nutritional supplements on a global scale.

The partnership represents the first time that the raw material producer and a finished goods manufacturer have joined together to enter this fast-growing market, the companies stated.

Yongyi Hi-Tech Nutraceuticals is on the verge of signing a licensing and distribution agreement with a large U.S. raw material distributor for its cholesterol-lowering ingredient, Choledrene. Under the terms of the licensing agreement, the U.S. distributor to be named later will supply Choledrene for distribution to dietary supplement manufacturers.

"Yongyi Hi-Tech Nutraceuticals is a supplier of natural supplement ingredients targeting large demographic categories," stated Brandon Schopp, VP sales at Hi-Tech. "The importance of cholesterol management is growing annually in light of new research concerning the cardiovascular benefit of lowering cholesterol. Choledrene has the ability to lower levels beyond levels previously recommended by most physicians. A clinically proven, proprietary ingredient, such as Choledrene is clearly a much sought after product and carries a distinct advantage when targeting this burgeoning cholesterol-lowering market."

 

keyboard_arrow_downCOMMENTS

Leave a Reply

No comments found

TRENDING STORIES

Polls

Which area of the industry do you think Amazon's entry would shake up the most?